Gene-sequencing technology producer Axbio raised nearly $100m in a round co-led by AstraZeneca-CICC Investment Fund while Eli Lilly helped Forbion Growth Opportunities Fund II to a $504m first close.

Funding AstraZeneca-CICC Investment Fund, the $1bn fund formed by pharmaceutical firm AstraZeneca and investment bank China International Capital Corporation, co-led a series B round for China-based gene-sequencing technology developer Axbio sized at almost $100m yesterday. The round was co-led with Yunfeng Capital and also featured CBC Group, CMG-SDIC Capital and 5Y Capital. Funds Another pharmaceutical…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.

Roshini Bains

Roshini Bains is the junior news reporter for Global Corporate Venturing and Global University Venturing.